Amicus Therapeutics, Inc. (NASDAQ:FOLD) saw unusually large options trading activity on Monday. Stock investors purchased 11,013 call options on the stock. This is an increase of 666% compared to the average volume of 1,438 call options.

In other news, insider Jay Barth sold 30,000 shares of Amicus Therapeutics stock in a transaction dated Monday, June 19th. The shares were sold at an average price of $10.00, for a total value of $300,000.00. Following the sale, the insider now owns 64,184 shares of the company’s stock, valued at $641,840. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Hung Do sold 29,914 shares of Amicus Therapeutics stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $8.00, for a total transaction of $239,312.00. Following the completion of the sale, the insider now directly owns 474,438 shares in the company, valued at approximately $3,795,504. The disclosure for this sale can be found here. Company insiders own 3.40% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. BNP Paribas Arbitrage SA raised its position in shares of Amicus Therapeutics by 3,672.2% in the second quarter. BNP Paribas Arbitrage SA now owns 68,012 shares of the biopharmaceutical company’s stock worth $685,000 after buying an additional 66,209 shares in the last quarter. Legal & General Group Plc raised its position in shares of Amicus Therapeutics by 1.6% in the second quarter. Legal & General Group Plc now owns 55,411 shares of the biopharmaceutical company’s stock worth $558,000 after buying an additional 852 shares in the last quarter. State of Wisconsin Investment Board bought a new position in shares of Amicus Therapeutics during the second quarter worth about $1,057,000. Rhumbline Advisers raised its position in shares of Amicus Therapeutics by 2.0% in the second quarter. Rhumbline Advisers now owns 138,438 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 2,690 shares in the last quarter. Finally, Smith Asset Management Group LP bought a new position in shares of Amicus Therapeutics during the second quarter worth about $316,000.

Shares of Amicus Therapeutics (NASDAQ:FOLD) opened at 12.58 on Thursday. Amicus Therapeutics has a 52 week low of $4.41 and a 52 week high of $14.05. The firm’s market cap is $1.80 billion. The company has a 50 day moving average of $11.40 and a 200 day moving average of $8.12.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. The firm had revenue of $7.16 million during the quarter, compared to analyst estimates of $6.96 million. Amicus Therapeutics had a negative net margin of 1,279.88% and a negative return on equity of 58.10%. During the same quarter in the prior year, the firm posted ($0.40) EPS. On average, equities research analysts anticipate that Amicus Therapeutics will post ($1.41) EPS for the current fiscal year.

Several analysts have recently weighed in on FOLD shares. Zacks Investment Research downgraded shares of Amicus Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, May 2nd. BidaskClub downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 2nd. Bank of America Corporation lowered their target price on shares of Amicus Therapeutics from $10.00 to $9.00 and set a “buy” rating on the stock in a report on Thursday, May 25th. Cowen and Company reaffirmed a “buy” rating and issued a $16.00 target price (up previously from $10.00) on shares of Amicus Therapeutics in a report on Tuesday, July 11th. Finally, Robert W. Baird reaffirmed an “outperform” rating and issued a $12.00 target price on shares of Amicus Therapeutics in a report on Friday, June 30th. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $13.75.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/amicus-therapeutics-sees-unusually-large-options-volume-fold/1467323.html.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.